Biblio

Author Title Type [ Year(Desc)]
Filters: Author is An, Wei  [Clear All Filters]
2012
Nadeau S, An W, Palermo N, Feng D, Ahmad G, Dong L, Borgstahl GEO, Natarajan A, Naramura M, Band V, et al. Oncogenic Signaling by Leukemia-Associated Mutant Cbl Proteins. Biochem Anal Biochem. 2012;Suppl 6(1).
2013
Yu L, Yang L, An W, Su X. Anticancer Bioactive Peptide-3 Inhibits Human Gastric Cancer Growth by Suppressing Gastric Cancer Stem Cells. J Cell Biochem. 2013.
2015
William BM, An W, Feng D, Nadeau S, Mohapatra BC, Storck MA, Band V, Band H. Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders. Hematology. 2015.
An W, Nadeau SA, Mohapatra BC, Feng D, Zutshi N, Storck MD, Arya P, Talmadge JE, Meza JL, Band V, et al. Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy. Oncotarget. 2015.
2016
Goetz B, An W, Mohapatra B, Zutshi N, Iseka F, Storck MD, Meza J, Sheinin Y, Band V, Band H. A novel CBL-Bflox/flox mouse model allows tissue-selective fully conditional CBL/CBL-B double-knockout: CD4-Cre mediated CBL/CBL-B deletion occurs in both T-cells and hematopoietic stem cells. Oncotarget. 2016.
2021
Dong Y, Kong W-N, An W. Downregulation of ALR impairs the therapeutic efficacy of LEPCs against acute liver injury by enhancing mitochondrial fission. Stem Cells. 2021.